APO Research
Talk to an analyst

APO RESEARCH · REPORT

Overactive Bladder Treatment

Overactive bladder (OAB) is a bladder disorder that results in an abnormal urge to urinate, urinary frequency, and nocturia (voiding at night). Some patients may also experience urinary incontinence (involuntary loss of bladder control). This report only focuses on the treatment drugs and Device.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Overactive bladder (OAB) is a bladder disorder that results in an abnormal urge to urinate, urinary frequency, and nocturia (voiding at night). Some patients may also experience urinary incontinence (involuntary loss of bladder control). This report only focuses on the treatment drugs and Device.

Selected research

Market Outlook & Growth Opportunities

Global Overactive Bladder Treatment Market Outlook and Growth Opportunities 2026

9 January 2026197 pages

Choose your research edition.

Industry ResearchOveractive Bladder Treatment Industry Research Report 2026110 pages · $2,950 USDIndustry Growth & TrendsGlobal Overactive Bladder Treatment Industry Growth and Trends Forecast to 203287 pages · $3,450 USDMarket StructureGlobal Overactive Bladder Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032180 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Overactive Bladder Treatment Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Overactive Bladder Treatment Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

Overactive bladder (OAB) is a bladder disorder that results in an abnormal urge to urinate, urinary frequency, and nocturia (voiding at night). Some patients may also experience urinary incontinence (involuntary loss of bladder control). This report only focuses on the treatment drugs and Device.

Global Overactive Bladder Treatment key players include Allergan, Astellas Pharma, Pfizer, Johnson & Johnson, Medtronic, etc. Global top five manufacturers hold a share about 90%. United States is the largest market, with a share about 60%, followed by Europe, with a share about 15 percent. In terms of product, Drugs is the largest segment, with a share about 95%. And in terms of application, the largest application is Idiopathic Overactive Bladder, followed by Neurogenic Overactive Bladder.

This report provides an overview of the global Overactive Bladder Treatment market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

Read the full market overview

The study covers key producers of Overactive Bladder Treatment and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Overactive Bladder Treatment revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Overactive Bladder Treatment market.

Overactive Bladder Treatment Segment by Company

Allergan

Astellas Pharma

Pfizer

Johnson & Johnson

Medtronic

KYORIN Pharmaceutical

Overactive Bladder Treatment Segment by Type

Drugs

Device

Overactive Bladder Treatment Segment by Application

Idiopathic Overactive Bladder

Neurogenic Overactive Bladder

Overactive Bladder Treatment Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Overactive Bladder Treatment status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Overactive Bladder Treatment key companies, revenue, market share, and recent developments.

3. To split the Overactive Bladder Treatment breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Overactive Bladder Treatment market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Overactive Bladder Treatment significant trends, drivers, influence factors in global and regions.

6. To analyze Overactive Bladder Treatment competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Overactive Bladder Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Overactive Bladder Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Overactive Bladder Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Overactive Bladder Treatment industry.

Chapter 3: Detailed analysis of Overactive Bladder Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Overactive Bladder Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Overactive Bladder Treatment in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Overactive Bladder Treatment Industry Trends Table 2. Overactive Bladder Treatment Industry Drivers Table 3. Overactive Bladder Treatment Industry Opportunities and Challenges Table 4. Overactive Bladder Treatment Industry Restraints Table 5. Global Overactive Bladder Treatment Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Overactive Bladder Treatment Revenue Share by Company (2021-2026) Table 7. Global Overactive Bladder Treatment Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Overactive Bladder Treatment Key Company Manufacturing Base & Headquarters Table 9. Global Overactive Bladder Treatment Company, Product Type & Application Table 10. Global Overactive Bladder Treatment Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Overactive Bladder Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Drugs Table 15. Significant Companies of Device Table 16. Global Overactive Bladder Treatment Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Overactive Bladder Treatment Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Overactive Bladder Treatment Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Overactive Bladder Treatment Sales Value Share by Type (2021-2026) Table 20. Global Overactive Bladder Treatment Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Idiopathic Overactive Bladder Table 22. Significant Companies of Neurogenic Overactive Bladder Table 23. Global Overactive Bladder Treatment Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 24. Global Overactive Bladder Treatment Sales Value by Application (2021-2026) & (US$ Million) Table 25. Global Overactive Bladder Treatment Sales Value by Application (2027-2032) & (US$ Million) Table 26. Global Overactive Bladder Treatment Sales Value Share by Application (2021-2026) Table 27. Global Overactive Bladder Treatment Sales Value Share by Application (2027-2032) Table 28. Global Overactive Bladder Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Overactive Bladder Treatment Sales Value by Region (2021-2026) & (US$ Million) Table 30. Global Overactive Bladder Treatment Sales Value Share by Region (2021-2026) Table 31. Global Overactive Bladder Treatment Sales Value by Region (2027-2032) & (US$ Million) Table 32. Global Overactive Bladder Treatment Sales Value Share by Region (2027-2032) Table 33. Global Overactive Bladder Treatment Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Overactive Bladder Treatment Sales Value by Country (2021-2026) & (US$ Million) Table 35. Global Overactive Bladder Treatment Sales Value Market Share by Country (2021-2026) Table 36. Global Overactive Bladder Treatment Sales Value by Country (2027-2032) & (US$ Million) Table 37. Global Overactive Bladder Treatment Sales Value Market Share by Country (2027-2032) Table 38. Allergan Company Information Table 39. Allergan Business Overview Table 40. Allergan Overactive Bladder Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 41. Allergan Overactive Bladder Treatment Product Portfolio Table 42. Allergan Recent Development Table 43. Astellas Pharma Company Information Table 44. Astellas Pharma Business Overview Table 45. Astellas Pharma Overactive Bladder Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. Astellas Pharma Overactive Bladder Treatment Product Portfolio Table 47. Astellas Pharma Recent Development Table 48. Pfizer Company Information Table 49. Pfizer Business Overview Table 50. Pfizer Overactive Bladder Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. Pfizer Overactive Bladder Treatment Product Portfolio Table 52. Pfizer Recent Development Table 53. Johnson & Johnson Company Information Table 54. Johnson & Johnson Business Overview Table 55. Johnson & Johnson Overactive Bladder Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. Johnson & Johnson Overactive Bladder Treatment Product Portfolio Table 57. Johnson & Johnson Recent Development Table 58. Medtronic Company Information Table 59. Medtronic Business Overview Table 60. Medtronic Overactive Bladder Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 61. Medtronic Overactive Bladder Treatment Product Portfolio Table 62. Medtronic Recent Development Table 63. KYORIN Pharmaceutical Company Information Table 64. KYORIN Pharmaceutical Business Overview Table 65. KYORIN Pharmaceutical Overactive Bladder Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. KYORIN Pharmaceutical Overactive Bladder Treatment Product Portfolio Table 67. KYORIN Pharmaceutical Recent Development Table 68. Research Programs/Design for This Report Table 69. Authors List of This Report Table 70. Secondary Sources Table 71. Primary Sources List of Figures Figure 1. Overactive Bladder Treatment Product Image Figure 2. Global Overactive Bladder Treatment Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Overactive Bladder Treatment Market Size (2021-2032) & (US$ Million) Figure 4. Global Overactive Bladder Treatment Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Drugs Image Figure 8. Device Image Figure 9. Global Overactive Bladder Treatment Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Overactive Bladder Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Overactive Bladder Treatment Sales Value Share by Type (2021-2032) Figure 12. Idiopathic Overactive Bladder Image Figure 13. Neurogenic Overactive Bladder Image Figure 14. Global Overactive Bladder Treatment Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Overactive Bladder Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Overactive Bladder Treatment Sales Value Share by Application (2021-2032) Figure 17. Global Overactive Bladder Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 18. Global Overactive Bladder Treatment Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 19. North America Overactive Bladder Treatment Sales Value (2021-2032) & (US$ Million) Figure 20. North America Overactive Bladder Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 21. Europe Overactive Bladder Treatment Sales Value (2021-2032) & (US$ Million) Figure 22. Europe Overactive Bladder Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Asia-Pacific Overactive Bladder Treatment Sales Value (2021-2032) & (US$ Million) Figure 24. Asia-Pacific Overactive Bladder Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 25. South America Overactive Bladder Treatment Sales Value (2021-2032) & (US$ Million) Figure 26. South America Overactive Bladder Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Middle East & Africa Overactive Bladder Treatment Sales Value (2021-2032) & (US$ Million) Figure 28. Middle East & Africa Overactive Bladder Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 29. USA Overactive Bladder Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 30. USA Overactive Bladder Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 31. USA Overactive Bladder Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 32. Canada Overactive Bladder Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. Canada Overactive Bladder Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. Canada Overactive Bladder Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Mexico Overactive Bladder Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Mexico Overactive Bladder Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Mexico Overactive Bladder Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Germany Overactive Bladder Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Germany Overactive Bladder Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Germany Overactive Bladder Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. France Overactive Bladder Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. France Overactive Bladder Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. France Overactive Bladder Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. U.K. Overactive Bladder Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. U.K. Overactive Bladder Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. U.K. Overactive Bladder Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Italy Overactive Bladder Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Italy Overactive Bladder Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Italy Overactive Bladder Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Spain Overactive Bladder Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Spain Overactive Bladder Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Spain Overactive Bladder Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Russia Overactive Bladder Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Russia Overactive Bladder Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Russia Overactive Bladder Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Netherlands Overactive Bladder Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Netherlands Overactive Bladder Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Netherlands Overactive Bladder Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Nordic Countries Overactive Bladder Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Nordic Countries Overactive Bladder Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Nordic Countries Overactive Bladder Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. China Overactive Bladder Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. China Overactive Bladder Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. China Overactive Bladder Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Japan Overactive Bladder Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Japan Overactive Bladder Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Japan Overactive Bladder Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. South Korea Overactive Bladder Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. South Korea Overactive Bladder Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. South Korea Overactive Bladder Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. India Overactive Bladder Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. India Overactive Bladder Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. India Overactive Bladder Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Australia Overactive Bladder Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Australia Overactive Bladder Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Australia Overactive Bladder Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Southeast Asia Overactive Bladder Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Southeast Asia Overactive Bladder Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Southeast Asia Overactive Bladder Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Brazil Overactive Bladder Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Brazil Overactive Bladder Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Brazil Overactive Bladder Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Argentina Overactive Bladder Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Argentina Overactive Bladder Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Argentina Overactive Bladder Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Chile Overactive Bladder Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Chile Overactive Bladder Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Chile Overactive Bladder Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Colombia Overactive Bladder Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Colombia Overactive Bladder Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Colombia Overactive Bladder Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Peru Overactive Bladder Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Peru Overactive Bladder Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Peru Overactive Bladder Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Saudi Arabia Overactive Bladder Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Saudi Arabia Overactive Bladder Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Overactive Bladder Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Israel Overactive Bladder Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Israel Overactive Bladder Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Israel Overactive Bladder Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. UAE Overactive Bladder Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. UAE Overactive Bladder Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. UAE Overactive Bladder Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Turkey Overactive Bladder Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Turkey Overactive Bladder Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Turkey Overactive Bladder Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Iran Overactive Bladder Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Iran Overactive Bladder Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Iran Overactive Bladder Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Egypt Overactive Bladder Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Egypt Overactive Bladder Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Egypt Overactive Bladder Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Years Considered Figure 114. Research Process Figure 115. Key Executives Interviewed

Scope & coverage.

Types
  • Drugs
  • Device
Applications
  • Idiopathic Overactive Bladder
  • Neurogenic Overactive Bladder
Companies covered
  • Allergan
  • Astellas Pharma
  • Pfizer
  • Johnson & Johnson
  • Medtronic
  • KYORIN Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Overactive Bladder Treatment Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Overactive Bladder Treatment Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Overactive Bladder Treatment Market Dynamics
  1. 2.1 Overactive Bladder Treatment Industry Trends
  2. 2.2 Overactive Bladder Treatment Industry Drivers
  3. 2.3 Overactive Bladder Treatment Industry Opportunities and Challenges
  4. 2.4 Overactive Bladder Treatment Industry Restraints
3 Overactive Bladder Treatment Market by Company
  1. 3.1 Global Overactive Bladder Treatment Company Revenue Ranking in 2025
  2. 3.2 Global Overactive Bladder Treatment Revenue by Company (2021-2026)
  3. 3.3 Global Overactive Bladder Treatment Company Ranking (2024-2026)
  4. 3.4 Global Overactive Bladder Treatment Company Manufacturing Base and Headquarters
  5. 3.5 Global Overactive Bladder Treatment Company Product Type and Application
  6. 3.6 Global Overactive Bladder Treatment Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Overactive Bladder Treatment Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Overactive Bladder Treatment Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Overactive Bladder Treatment Market by Type
  1. 4.1 Overactive Bladder Treatment Type Introduction
  2. 4.1.1 Drugs
  3. 4.1.2 Device
  4. 4.2 Global Overactive Bladder Treatment Sales Value by Type
  5. 4.2.1 Global Overactive Bladder Treatment Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Overactive Bladder Treatment Sales Value by Type (2021-2032)
  7. 4.2.3 Global Overactive Bladder Treatment Sales Value Share by Type (2021-2032)
5 Overactive Bladder Treatment Market by Application
  1. 5.1 Overactive Bladder Treatment Application Introduction
  2. 5.1.1 Idiopathic Overactive Bladder
  3. 5.1.2 Neurogenic Overactive Bladder
  4. 5.2 Global Overactive Bladder Treatment Sales Value by Application
  5. 5.2.1 Global Overactive Bladder Treatment Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Overactive Bladder Treatment Sales Value by Application (2021-2032)
  7. 5.2.3 Global Overactive Bladder Treatment Sales Value Share by Application (2021-2032)
6 Overactive Bladder Treatment Regional Value Analysis
  1. 6.1 Global Overactive Bladder Treatment Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Overactive Bladder Treatment Sales Value by Region (2021-2032)
  3. 6.2.1 Global Overactive Bladder Treatment Sales Value by Region: 2021-2026
  4. 6.2.2 Global Overactive Bladder Treatment Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Overactive Bladder Treatment Sales Value (2021-2032)
  7. 6.3.2 North America Overactive Bladder Treatment Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Overactive Bladder Treatment Sales Value (2021-2032)
  10. 6.4.2 Europe Overactive Bladder Treatment Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Overactive Bladder Treatment Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Overactive Bladder Treatment Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Overactive Bladder Treatment Sales Value (2021-2032)
  16. 6.6.2 South America Overactive Bladder Treatment Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Overactive Bladder Treatment Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Overactive Bladder Treatment Sales Value Share by Country, 2025 VS 2032
7 Overactive Bladder Treatment Country-level Value Analysis
  1. 7.1 Global Overactive Bladder Treatment Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Overactive Bladder Treatment Sales Value by Country (2021-2032)
  3. 7.2.1 Global Overactive Bladder Treatment Sales Value by Country (2021-2026)
  4. 7.2.2 Global Overactive Bladder Treatment Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Overactive Bladder Treatment Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Overactive Bladder Treatment Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Overactive Bladder Treatment Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Overactive Bladder Treatment Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Overactive Bladder Treatment Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Overactive Bladder Treatment Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Overactive Bladder Treatment Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Overactive Bladder Treatment Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Overactive Bladder Treatment Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Overactive Bladder Treatment Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Overactive Bladder Treatment Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Overactive Bladder Treatment Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Overactive Bladder Treatment Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Overactive Bladder Treatment Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Overactive Bladder Treatment Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Overactive Bladder Treatment Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Overactive Bladder Treatment Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Overactive Bladder Treatment Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Overactive Bladder Treatment Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Overactive Bladder Treatment Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Overactive Bladder Treatment Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Overactive Bladder Treatment Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Overactive Bladder Treatment Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Overactive Bladder Treatment Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Overactive Bladder Treatment Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Overactive Bladder Treatment Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Overactive Bladder Treatment Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Overactive Bladder Treatment Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Overactive Bladder Treatment Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Overactive Bladder Treatment Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Overactive Bladder Treatment Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Overactive Bladder Treatment Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Overactive Bladder Treatment Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Overactive Bladder Treatment Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Overactive Bladder Treatment Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Overactive Bladder Treatment Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Overactive Bladder Treatment Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Overactive Bladder Treatment Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Overactive Bladder Treatment Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Overactive Bladder Treatment Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Overactive Bladder Treatment Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Overactive Bladder Treatment Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Overactive Bladder Treatment Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Overactive Bladder Treatment Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Overactive Bladder Treatment Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Overactive Bladder Treatment Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Overactive Bladder Treatment Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Overactive Bladder Treatment Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Overactive Bladder Treatment Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Overactive Bladder Treatment Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Overactive Bladder Treatment Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Overactive Bladder Treatment Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Overactive Bladder Treatment Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Overactive Bladder Treatment Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Overactive Bladder Treatment Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Overactive Bladder Treatment Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Overactive Bladder Treatment Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Overactive Bladder Treatment Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Overactive Bladder Treatment Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Overactive Bladder Treatment Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Overactive Bladder Treatment Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Overactive Bladder Treatment Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Overactive Bladder Treatment Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Overactive Bladder Treatment Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Overactive Bladder Treatment Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Overactive Bladder Treatment Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Overactive Bladder Treatment Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Overactive Bladder Treatment Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Overactive Bladder Treatment Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Overactive Bladder Treatment Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Overactive Bladder Treatment Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Overactive Bladder Treatment Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Overactive Bladder Treatment Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Overactive Bladder Treatment Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Overactive Bladder Treatment Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Overactive Bladder Treatment Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Overactive Bladder Treatment Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Overactive Bladder Treatment Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Overactive Bladder Treatment Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Overactive Bladder Treatment Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Overactive Bladder Treatment Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Overactive Bladder Treatment Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Overactive Bladder Treatment Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Overactive Bladder Treatment Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Allergan
  2. 8.1.1 Allergan Company Information
  3. 8.1.2 Allergan Business Overview
  4. 8.1.3 Allergan Overactive Bladder Treatment Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Allergan Overactive Bladder Treatment Product Portfolio
  6. 8.1.5 Allergan Recent Developments
  7. 8.2 Astellas Pharma
  8. 8.2.1 Astellas Pharma Company Information
  9. 8.2.2 Astellas Pharma Business Overview
  10. 8.2.3 Astellas Pharma Overactive Bladder Treatment Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Astellas Pharma Overactive Bladder Treatment Product Portfolio
  12. 8.2.5 Astellas Pharma Recent Developments
  13. 8.3 Pfizer
  14. 8.3.1 Pfizer Company Information
  15. 8.3.2 Pfizer Business Overview
  16. 8.3.3 Pfizer Overactive Bladder Treatment Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Pfizer Overactive Bladder Treatment Product Portfolio
  18. 8.3.5 Pfizer Recent Developments
  19. 8.4 Johnson & Johnson
  20. 8.4.1 Johnson & Johnson Company Information
  21. 8.4.2 Johnson & Johnson Business Overview
  22. 8.4.3 Johnson & Johnson Overactive Bladder Treatment Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Johnson & Johnson Overactive Bladder Treatment Product Portfolio
  24. 8.4.5 Johnson & Johnson Recent Developments
  25. 8.5 Medtronic
  26. 8.5.1 Medtronic Company Information
  27. 8.5.2 Medtronic Business Overview
  28. 8.5.3 Medtronic Overactive Bladder Treatment Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Medtronic Overactive Bladder Treatment Product Portfolio
  30. 8.5.5 Medtronic Recent Developments
  31. 8.6 KYORIN Pharmaceutical
  32. 8.6.1 KYORIN Pharmaceutical Company Information
  33. 8.6.2 KYORIN Pharmaceutical Business Overview
  34. 8.6.3 KYORIN Pharmaceutical Overactive Bladder Treatment Revenue and Gross Margin (2021-2026)
  35. 8.6.4 KYORIN Pharmaceutical Overactive Bladder Treatment Product Portfolio
  36. 8.6.5 KYORIN Pharmaceutical Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst